Bio-Rad Laboratories

US · BIO #1479 by market cap Listed 1970

367.92 -0.91 -0.25%

Live - 5344 symbols - heartbeat 193s ago · 2026-10-07 19:54

After-hours 367.12 -0.22%

Market cap: 9.84B
P/E (TTM): 44.81
P/B: 1.37
EPS: 27.85
Div yield: 0.00%
52W pos: 82%

Reader sentiment Are you bullish or bearish on BIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 3.56, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +0.65% YoY

Margins

Gross margin: 51.87%
Operating margin: 8.46%
Net margin: 29.42%

Key ratios & quality

Enterprise value: 9.54B
Altman Z-Score: 3.56

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	2.29B	2.31B	2.55B	2.92B	2.80B	2.67B	2.57B	2.58B
Gross profit	1.22B	1.26B	1.44B	1.64B	1.57B	1.43B	1.38B	1.34B
Selling & admin expenses	834.78M	824.63M	798.80M	877.12M	827.80M	841.70M	814.00M	844.30M
Research & development	199.20M	202.71M	217.76M	260.64M	256.90M	247.40M	295.90M	275.60M
Operating profit	189.17M	229.66M	421.33M	500.34M	475.10M	337.80M	269.00M	218.60M
Pretax profit	512.66M	2.26B	4.92B	5.45B	-4.70B	-850.10M	-2.34B	995.50M
Tax	147.05M	502.41M	1.10B	1.19B	-1.08B	-212.80M	-498.30M	235.60M
Net profit	365.61M	1.76B	3.81B	4.25B	-3.63B	-637.30M	-1.84B	759.90M
Basic EPS	12	59	128	143	-122	-22	-65	28
Diluted EPS	12.10	58.27	126.47	140.83	-121.79	-21.82	-65.36	27.85

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	585.40M	651.60M	653.00M	693.20M	592.10M	651.00M
Gross profit	306.00M	345.30M	343.40M	345.20M	309.40M	345.80M
Selling & admin expenses	208.80M	207.70M	206.80M	221.00M	212.40M	212.00M
Research & development	73.50M	60.50M	71.30M	70.30M	62.90M	61.20M
Operating profit	23.70M	77.10M	63.90M	53.90M	34.10M	72.60M
Pretax profit	83.40M	414.00M	-431.10M	929.20M	-689.80M	542.10M
Tax	19.40M	96.20M	-89.20M	209.20M	-162.70M	170.70M
Net profit	64.00M	317.80M	-341.90M	720.00M	-527.10M	371.40M
Basic EPS	2	12	-13	27	-20	14
Diluted EPS	2.29	11.67	-12.70	26.65	-19.55	13.85

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	2.02B	2.18B	2.14B	1.99B	3.16B	3.05B	3.03B	2.91B
Cash & ST investments	844.80M	1.11B	991.12M	869.92M	1.79B	1.61B	1.66B	1.54B
Inventory	583.82M	554.01M	622.25M	572.24M	719.32M	780.50M	760.00M	740.70M
Total assets	5.61B	8.01B	12.97B	17.80B	13.50B	12.30B	9.36B	10.58B
Total current liabilities	450.80M	905.50M	631.54M	680.94M	568.71M	522.80M	467.80M	517.00M
Short-term debt	493.00K	461.57M	38.31M	36.92M	36.80M	40.90M	42.90M	37.40M
Long-term debt	438.94M	2.40M	1.30M	10.51M	1.20B	1.20B	1.20B	1.20B
Total liabilities	1,590,737,000.00	2,253,802,000.00	3,092,678,000.00	4,114,157,000.00	3,886,414,000.00	3,557,900,000.00	2,794,800,000.00	3,122,900,000.00
Total equity	4.02B	5.76B	9.88B	13.69B	9.62B	8.74B	6.57B	7.45B
Retained earnings	3.72B	5.47B	9.27B	13.53B	9.90B	9.26B	7.42B	8.18B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	3.04B	2.81B	2.84B	2.91B	2.94B	3.02B
Cash & ST investments	1.66B	1.37B	1.42B	1.54B	1.56B	1.62B
Inventory	790.10M	798.80M	783.20M	740.70M	770.50M	780.60M
Total assets	9.53B	10.21B	9.70B	10.58B	9.79B	10.25B
Total current liabilities	506.60M	548.90M	522.30M	517.00M	917.00M	961.30M
Short-term debt	42.50M	40.60M	38.10M	37.40M	436.70M	434.30M
Long-term debt	1.20B	1.20B	1.20B	1.20B	802.90M	803.00M
Total liabilities	2,847,500,000.00	3,085,400,000.00	2,959,600,000.00	3,122,900,000.00	2,938,700,000.00	3,078,100,000.00
Total equity	6.68B	7.13B	6.74B	7.45B	6.85B	7.17B
Retained earnings	7.48B	7.80B	7.46B	8.18B	7.65B	8.02B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	285.49M	457.90M	584.97M	669.46M	194.40M	374.90M	455.20M	532.20M
Depreciation & amortization	138.10M	134.20M	138.60M	137.60M	137.30M	145.90M	151.60M	165.40M
Free cash flow	155.67M	359.37M	476.41M	535.72M	80.10M	218.20M	266.20M	374.60M
Dividends paid	--	--	--	--	--	--	--	--
Stock buybacks / issuance	-48.91M	-28.00M	-100.00M	-50.00M	-215.70M	-428.70M	-203.60M	-295.50M
Ending cash balance	434.16M	662.65M	667.12M	471.13M	434.50M	404.40M	489.80M	532.20M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	129.90M	116.50M	120.90M	164.90M	108.10M	98.70M
Depreciation & amortization	38.10M	40.60M	44.20M	42.50M	40.90M	41.10M
Free cash flow	95.50M	70.80M	89.20M	119.10M	78.10M	66.70M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	-101.90M	-140.20M	-53.40M	0	-47.80M	-31.50M
Ending cash balance	523.10M	371.70M	398.20M	532.20M	509.00M	518.80M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	10.52	35.98	48.69	36.06	-31.16	-6.94	-24.09	10.84
ROA %	7.40	25.83	36.28	27.62	-23.20	-4.94	-17.03	7.62
ROIC %	9.30	32.27	46.14	35.28	-29.27	-6.39	-20.68	8.63
5-year avg ROE %	4.94	11.33	20.15	27.17	20.05	16.56	4.55	-3.05
EBIT margin %	23.44	98.83	193.65	186.13	-166.51	-29.97	-89.37	40.43
FCF / sales %	6.80	15.55	18.71	18.33	2.87	8.17	10.37	14.50
Current ratio	4.49	2.41	3.39	2.92	5.55	5.83	6.48	5.62
Quick ratio	2.74	1.66	2.23	1.90	4.02	4.01	4.53	3.87
Debt / assets	7.83	8.13	1.74	1.26	10.28	11.43	14.68	13.11
LT debt / equity	10.92	3.29	1.90	1.36	14.05	15.61	20.27	18.09
Interest coverage	22.39	97.56	225.49	3,507.22	-122.43	-16.20	-46.90	21.32
Revenue CAGR (3Y) %	4.27	3.78	5.63	8.48	6.62	1.62	-4.24	-2.68
Net income CAGR (3Y) %	49.58	307.45	214.81	126.60	--	--	--	--
FCF CAGR (3Y) %	28.81	68.97	--	50.98	-39.37	-22.92	-20.79	67.23

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	-27.51	4.59	-9.50	10.84	2.50	3.11
ROA %	-19.55	3.21	-6.66	7.62	1.75	2.17
ROIC %	-23.70	3.54	-8.24	8.63	1.78	2.31
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	-106.32	19.54	-31.03	40.43	10.49	15.42
FCF / sales %	13.07	13.61	13.17	14.50	13.79	13.64
Current ratio	5.99	5.12	5.44	5.62	3.21	3.14
Quick ratio	4.12	3.36	3.61	3.87	2.17	2.14
Debt / assets	14.38	13.77	14.39	13.11	14.08	13.37
LT debt / equity	19.87	19.16	20.15	18.09	13.74	13.05
Interest coverage	-55.59	10.19	-16.16	21.32	5.51	8.18
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Clinical Diagnostics is the largest reported line at 61.29% of revenue, across 2 reported segments.
Life Science follows at 38.71%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Clinical Diagnostics61.29%

Life Science38.71%

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.